CagriSema achieved 22.7% in 68 weeks
Retatrutide is one of the most talked about weight-loss injections despite not being approved for public use anywhere
We would like to thank IS for his funding support towards the publication and the Institute for Neurocience, UTGV School of Medicine
What it does not show: efficacy in chronic tendinopathy, in non-rodent species under controlled conditions, in humans, or under sham-injection-controlled and pre-registered protocols
The answer depends on your body composition and comfort level, though most patients find success with the abdomen or thigh
The powder may have degraded before reconstitution due to improper storage, high temperature exposure, or moisture infiltration into the sealed vial